Trial reportJournal of cosmetic dermatology2025
Performance and Safety of the Medical Device Ialuxid Gel in the Treatment of Mild-Moderate Acne Vulgaris: An Open-Label, Noncomparative Multicentre Interventional Clinical Trial.
Trial report in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05345093 (Open, Non-comparative, Multicentre, Interventional Clinical Investigation to Evaluate the Performance and Safety of the Medical Device Ialuxid® Gel), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Open, Non-comparative, Multicentre, Interventional Clinical Investigation to Evaluate the Performance and Safety of the Medical Device Ialuxid® Gel (Hydrogen Peroxide and Hyaluronic Acid) in the Treatment of Acne Vulgaris and Folliculitis.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMedical literature shows there is no ideal treatment for acne, but topical therapies like benzoyl peroxide, retinoids, and antibiotics have proven to improve mild-moderate cases. Replacing benzoyl peroxide (potentially irritating) with hydrogen peroxide has already been suggested in the medical literature.
aimsWe investigated a medical device, a proprietary combination of hyaluronic acid, hydrogen peroxide, and glycine in mild-moderate acne vulgaris.
methodsPatients of both sexes between ≥ 18 and ≤ 45 years old, with a Global Acne Grading System score ≤ 30, were included. Exclusion criteria were dermal systemic or infectious diseases; allergy to the tested product; pregnant or lactating women; treatment for acne 30 days before baseline; and previous facial aesthetic surgery. Forty patients were treated for 8 weeks several times a day with the tested product and visited at baseline, week 2, week 4, and week 8. Outcomes were decreasing the total number of lesions and the Global Acne Grading System Severity Score, Investigator Global Assessment of Performance with photographs evaluation in blind, Dermatology Life Quality Index, and the Treatment Satisfaction Questionnaire. Adverse events were collected for safety.
resultsA 2-fold decrease in the number of lesions at the final visit (-56.3%, p < 0.001). The remaining outcomes evidenced a statistically significant reduction at the final visit. Only 8 adverse events (all mild and related to the tested device) were reported.
conclusionsResults and optimal safety demonstrate that the tested product has a clinical benefit and could be associated with retinoids, as first choice for mild to moderate acne.
trial registrationClinicaltrial.gov as NCT05345093.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.